BioTissue Technologies AG
Ad hoc-Service: BioTissue AG english
Ad-hoc announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
BioTissue Technologies AG sales higher than expected
BioTissue Technologies AG (SIN 618061), the Freiburg-based company listed on the
Neuer Markt segment of the Frankfurt Stock Exchange, scored sales of DM 0.766
million in business year 2000, thus exceeding the targeted figure of DM 0.603
million by 27 percent.
The sales figure contains DM 0.131 million from management services provided.
BioTissue Technologies AG’s business includes not only the development,
production, and distribution of tissue-engineering products (natural tissue
substitutes) but also a technology transfer model involving research centers and
spin-offs and enabling the Company to lock into the usufruct to new products.
The revenue from management services will play a subordinate role in the years
ahead.
According to the preliminary annual financial statements, the loss before
interest and taxes will come to DM 6.764 million, 4.85 percent down on the
expected loss of DM 6.451 million, and attributable above all to stronger human
resource marketing, as well as recruitment and staff loyalty measures that were
brought forward. During and after its IPO, BioTissue intensified its recruitment
drive in order to exploit the fact that by going public it had boosted
awareness of the Company.
For further information contact: BioTissue Technologies AG, Martin Braendle,
Investor Relations Manager, Phone: +49-761-7675110, E-Mail: braendle@biotissue-
tec.com, Internet: www.biotissue-tec.com
end of Ad hoc-announcement, (c) DGAP 28.02.2001
———————————————————————–
WKN: 618061; Index: Nemax Allshare
Listed: Neuer Markt in Frankfurt,
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und
Stuttgart
280822 Feb 01
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden